How I Use First-Generation vs Second-Generation BTK Inhibitors in CLL and MCL
Understanding Research Advances in Genitourinary Cancers: CCO Independent Conference Highlights From the 2018 Genitourinary Cancers Symposium
New Data in the Treatment of Lymphoma and CLL: Independent Conference Coverage of Hematology 2017
Novel Targeted Therapies and Strategies in Hematologic Diseases
A New Era in Prostate Cancer Treatment? Understanding DNA Repair Deficiencies and the Therapeutic Rationale for PARP Inhibition
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.